Assessment of Cardiac Output in Patients With ARDS Implanted With Venous-venous ECMO. (PiCCMO)
Primary Purpose
Acute Respiratory Distress Syndrome
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Transpulmonary thermodilution
Sponsored by
About this trial
This is an interventional supportive care trial for Acute Respiratory Distress Syndrome focused on measuring ARDS, Venovenous Extracorporeal Membrane Oxygenation, Pulmonary Thermodilution, Cardiac Output
Eligibility Criteria
Inclusion Criteria:
- ≥18yrs.
- With acute respiratory distress syndrome.
- Monitored by transpulmonary thermodilution device.
- Implanted by VV-ECMO.
- Affiliated to the French Health Insurance
Exclusion Criteria:
- Pregnancy
- Patient placed under judicial protection
- Patient on state medical aid (AME, Aide Medicale d'Etat)
Sites / Locations
- Service de médecine intensive-réanimation de l'Hôpital BicêtreRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS
Arm Description
Standard of care procedure for patient with severe ARDS
Outcomes
Primary Outcome Measures
The measurements of CO by transpulmonary thermodilution compared to CO measured by echocardiography
Standard measurements by injection of three cold bolus in the venous circulation for transpulmonary thermodilution and standard echocardiography procedures.
Secondary Outcome Measures
The CO measurements by pulse contour analyse at different ECMO blood flow/CO ratio.
The changes of transpulmonary thermodilution parameter :GEDVI measured at different ECMO blood flow/CO ratio.
GEDVI (Global end diastolic volume index) measured in mL/m^2
The changes of transpulmonary thermodilution parameter : CFI measured at different ECMO blood flow/CO ratio.
CFI (Cardiac function index) measured in 1/min
The changes of transpulmonary thermodilution parameters : EVLWI measured at different ECMO blood flow/CO ratio.
EVLWI (Extravascular Lung Water index) measured in mL/kg
The changes of transpulmonary thermodilution parameter : PVPI (Pulmonary Vascular Permeability Index) measured at different ECMO blood flow/CO ratio.
Full Information
NCT ID
NCT05164484
First Posted
October 1, 2021
Last Updated
November 14, 2022
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT05164484
Brief Title
Assessment of Cardiac Output in Patients With ARDS Implanted With Venous-venous ECMO.
Acronym
PiCCMO
Official Title
Assessment of Cardiac Output by Transpulmonary Thermodilution and Pulse Contour Analysis in Patients With ARDS Implanted by Venous-venous ECMO
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2021 (Actual)
Primary Completion Date
December 15, 2024 (Anticipated)
Study Completion Date
January 15, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In patients with severe acute respiratory distress syndrome, extracorporeal membrane oxygenation (ECMO), which also as known as extracorporeal life support, may be used. This technique helps the lungs by providing oxygenation to the blood via an external gas exchanger and thus participates partially or fully in gas exchange. The ECMO device includes a pump for draining and returning blood at a certain blood flow rate (ECMO blood flow). An ECMO rate that is adapted to the patient's cardiac output (CO) is essential for effective oxygenation for patients. The objective for clinicians is an ECMO blood flow to cardiac output ≥40%, which can go up to 100% as needed. In addition to the expected benefit in the management of the patient with ARDS, measuring CO is, therefore, all the more important in patients requiring ECMO.
Monitoring CO in a patient with ECMO is not only for determining the minimum ECMO blood flow rate but also for optimizing the functioning of the ECMO. However, the validity of techniques for measuring CO in patients with ECMO has been poorly studied. The reliability of the CO measurement by transpulmonary thermodilution is questioned since the extracorporeal circulation may influence the pathway of cold indicator injected into the patients' circulation and the thermodilution curve measured from the femoral arterial is thereby modified.
Detailed Description
Acute respiratory distress syndrome (ARDS) is a severe and common condition with up to 45% mortality in ICU. Its respiratory management includes "protective" mechanical ventilation, the use of a positive end-expiratory pressure level, sometimes the performance of recruitment maneuvers or prone position, and the use of neuromuscular blockers. Due to heart-lung interactions, these different strategies can induce significant or even deleterious hemodynamic effects. Thus, hemodynamic monitoring in such patients is essential. It could assess the effect of ventilatory settings and optimize hemodynamic management. Optimization of arterial oxygen transport in hypoxemic patients may require an increase in the patient's cardiac output (CO). Fluid administration is one of the first-line strategies for achieving this objective. However, unnecessary fluid administration can lead to an increase in pulmonary edema and thus increase the duration of mechanical ventilation and hospitalization. Transpulmonary thermodilution is one of the advanced hemodynamic monitoring in ICU, which consists of the injection of three boluses of cold saline of 15 ml through a central venous catheter located in the superior vena cava, causing a drop in blood temperature which is detected by a femoral arterial catheter equipped with a thermistor. It was demonstrated to be a reliable and simple technique at the bedside for measuring CO. Combined with another technique, pulse contour analysis analysis, transpulmonary thermodilution allows to measure CO beat-to-beat. In addition, transpulmonary thermodilution can measure various hemodynamic variables of interest such as the global end-diastolic volume index (GEDVI, cardiac preload index), the cardiac function index (CFI, cardiac contractility index), extravascular lung water index (EVLWI, volume of fluid accumulated in the alveolar and interstitial lung sectors) and the pulmonary vascular permeability index (PVPI). The last two indices are particularly interesting in patients with ARDS, and were shown to be associated with mortality in patients with ARDS independently. In severe ARDS, ECMO may be another choice. This technique helps the lungs to rest by providing oxygenation to the blood via an external gas exchanger and thus participates partially or fully in gas exchange. The ECMO includes a central pump for draining and returning blood at a given blood flow rate (ECMO blood flow rate). The recommended oxygenation target for patients receiving venous-venous extracorporeal membrane oxygenation (VV-ECMO) assistance is when peripheral oxygen saturation (SpO2) is ≥80%. An ECMO blood flow rate adapted to the patient's CO is essential for effective extracorporeal oxygenation. The objective is an ECMO blood flow /CO ≥40%. It can also go up to 100% as needed (8). This rate can be modified by adjusting the central pump. Thus, it is obvious that measuring CO is important in patients requiring ECMO. However, the techniques measuring CO in patients with ECMO have been poorly studied. the reliability of the measurement of transpulmonary thermodilution was questioned since the analysis of the thermodilution curve can be modified by the extracorporeal circulation. This effect does not matter in a low flow extracorporeal deviation, such as that which is achieved for example during a continuous extrarenal purification . Some studies have shown that transpulmonary thermodilution measurements remain reliable when using another extracorporeal circuit, extracorporeal carbon dioxide removal, whose flow rate can go up to 2.4 L / min. It could be different from ECMO, the blood flow of which is higher. The only available study, conducted by Herner et al, demonstrated the reliability of measuring CO by transpulmonary thermodilution during ECMO. However, the ECMO blood flow/CO ratio was only around 40% in this study. For higher ECMO blood flow/CO ratio (> 40%), the problem remains unresolved.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Distress Syndrome
Keywords
ARDS, Venovenous Extracorporeal Membrane Oxygenation, Pulmonary Thermodilution, Cardiac Output
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS
Arm Type
Other
Arm Description
Standard of care procedure for patient with severe ARDS
Intervention Type
Device
Intervention Name(s)
Transpulmonary thermodilution
Intervention Description
Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
Primary Outcome Measure Information:
Title
The measurements of CO by transpulmonary thermodilution compared to CO measured by echocardiography
Description
Standard measurements by injection of three cold bolus in the venous circulation for transpulmonary thermodilution and standard echocardiography procedures.
Time Frame
The first week during patient is under ECMO assistance
Secondary Outcome Measure Information:
Title
The CO measurements by pulse contour analyse at different ECMO blood flow/CO ratio.
Time Frame
The first week during patient is under ECMO assistance
Title
The changes of transpulmonary thermodilution parameter :GEDVI measured at different ECMO blood flow/CO ratio.
Description
GEDVI (Global end diastolic volume index) measured in mL/m^2
Time Frame
The first week during patient is under ECMO assistance
Title
The changes of transpulmonary thermodilution parameter : CFI measured at different ECMO blood flow/CO ratio.
Description
CFI (Cardiac function index) measured in 1/min
Time Frame
The first week during patient is under ECMO assistance
Title
The changes of transpulmonary thermodilution parameters : EVLWI measured at different ECMO blood flow/CO ratio.
Description
EVLWI (Extravascular Lung Water index) measured in mL/kg
Time Frame
The first week during patient is under ECMO assistance
Title
The changes of transpulmonary thermodilution parameter : PVPI (Pulmonary Vascular Permeability Index) measured at different ECMO blood flow/CO ratio.
Time Frame
The first week during patient is under ECMO assistance
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥18yrs.
With acute respiratory distress syndrome.
Monitored by transpulmonary thermodilution device.
Implanted by VV-ECMO.
Affiliated to the French Health Insurance
Exclusion Criteria:
Pregnancy
Patient placed under judicial protection
Patient on state medical aid (AME, Aide Medicale d'Etat)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christopher LAI, M.D.
Phone
33 (0)1 45 21 26 71
Email
christopher.lai@aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Xavier MONNET, M.D., Ph.D.
Phone
33 (0)6 60 86 26 69
Email
xavier.monnet@aphp.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher LAI, M.D.
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de médecine intensive-réanimation de l'Hôpital Bicêtre
City
Le Kremlin-Bicêtre
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher LAI, M.D.
Phone
33 (0)1 45 21 26 71
Email
christopher.lai@aphp.fr
First Name & Middle Initial & Last Name & Degree
Xavier MONNET, M.D., Ph.D.
Phone
33 (0)6 60 86 26 69
Email
xavier.monnet@aphp.fr
First Name & Middle Initial & Last Name & Degree
Christopher LAI, M.D.
12. IPD Sharing Statement
Learn more about this trial
Assessment of Cardiac Output in Patients With ARDS Implanted With Venous-venous ECMO.
We'll reach out to this number within 24 hrs